- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02503137
Badanie SM04554 stosowanego miejscowo na skórę głowy mężczyzn z łysieniem androgenowym, analizowane przez biopsję skóry głowy przed i po podaniu
Faza 2, wieloośrodkowe, randomizowane, podwójnie ślepe badanie SM04554 stosowanego miejscowo na skórę głowy mężczyzn z łysieniem androgenowym (AGA) analizowane przez biopsję skóry głowy przed i po podaniu
This study will assess the safety, tolerability, and efficacy of SM04554 at concentrations of 0.15% and 0.25%. Improved knowledge of the changes in hair counts and immunohistochemical analysis associated with androgenetic alopecia (AGA) before and after treatment with SM04554 and compared to placebo may lead to a greater understanding of the underlying mechanisms of action of SM04554.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Michigan
-
Clinton Township, Michigan, Stany Zjednoczone
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Stany Zjednoczone
- Research Site
-
-
Texas
-
College Station, Texas, Stany Zjednoczone
- Research Site
-
Houston, Texas, Stany Zjednoczone
- Research Site
-
-
Virginia
-
Lynchburg, Virginia, Stany Zjednoczone
- Research Site
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 4, 5, 5A, 5V, or 6
- In good general health, as determined by the Investigator
- Willing and able to attend all study visits
- Willing to undergo two punch biopsies of the scalp
- Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
- Willing to not use permanent or semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products will be allowed on non-study visit days (e.g., hair gel, mousse, styling spray)
- Willing to use sponsor-supplied shampoo and conditioner in place of regular shampoo and conditioner, for the duration of the study; use of sponsor-supplied conditioner is optional for subjects who do not use conditioner
Exclusion Criteria:
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- Males who are sexually active and have a partner who is capable of becoming pregnant, neither of whom have had surgery to become sterilized, that are not using a highly effective method of birth control and are not willing to use a highly effective method of birth control during the study treatment period until 90 days post last dose of study medication
- Current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, seborrheic dermatitis, actinic keratosis), cuts and/or abrasions on the scalp or hands or condition (e.g., sunburn, tattoos) on the treatment area or hands that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations
- History of or current skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma) located anywhere on the body
- History of surgical correction of hair loss on the scalp
- Previous exposure to SM04554
- Use of blood thinners (e.g., Coumadin, Plavix, Lovenox, and aspirin >81mg); low dose aspirin (e.g., ≤81 mg) is allowable
- Use of any products or devices clinically proven to promote scalp hair growth (e.g., finasteride or minoxidil) within 24 weeks prior to study start
- Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to study start
- Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to study start
- Use of medicated shampoo or conditioner (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to study start
- History of hair transplants
- Current use of an occlusive wig, hair extensions, or hair weaves
- Participation in any other investigational drug or medical device trial which included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to study start
- Poor peripheral venous access
- Subjects unwilling to refrain from sperm donation during the study treatment period until 90 days post last dose of study medication
- Subjects with pregnant partners at study start
- Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
- Subjects employed by Samumed, LLC, or any of its affiliates or development partners (that is, an employee, temporary contract worker, or designee) responsible for the conduct of the study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Topical SM04554 0.15% solution
Topical SM04554 0.15% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Eksperymentalny: Topical SM04554 0.25% solution
Topical SM04554 0.25% solution, once daily for approximately 90 days |
Study medication application will be performed by the individual subject at approximately the same time each day. |
|
Komparator placebo: Vehicle
Topical vehicle solution, once daily for approximately 90 days |
Vehicle solution application will be performed by the individual subject at approximately the same time each day. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change From Baseline/Day 91 in Number of Terminal Hair Follicles (Terminal Anagen + Terminal Catagen and Telogen Follicles)
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Anagen Hair Follicles
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Terminal Catagen and Telogen Hair Follicles
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Miniaturized Hair Follicles (Indeterminate + Vellus Follicles)
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Indeterminate Hair Follicles
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Change From Baseline/Day 91 in Number of Vellus Hair Follicles
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Terminal and Miniaturized Hair Follicle Density/mm²
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ratio of Terminal to Miniaturized Hair Follicles
Ramy czasowe: Day 91 and Day 135
|
Scalp biopsies were used to analyze the outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Change from baseline is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Beta-catenin in Epidermis and Infundibulum
Ramy czasowe: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Epidermis and Infundibulum
Ramy czasowe: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
|
Ki-67 in Hair Bulb
Ramy czasowe: Day 91 and Day 135
|
Immunohistochemistry of scalp biopsies were used to analyze the nuclear expression outcome measure at baseline (prior to initiating therapy) and at each subsequent timepoint. Percentage of positively-stained nuclei were reported at each timepoint. Change from baseline in percentage of positively-stained nuclei is the difference between follow-up and baseline. Change from Day 91 is the difference between Day 135 and Day 91. |
Day 91 and Day 135
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- SM04554-AGA-04
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .